Results 61 to 70 of about 7,148 (201)

Exploring medication-overuse and medication-overuse headache in cluster headache

Cephalalgia
Background It is not well established to what extent medication-overuse occurs in cluster headache (CH), if medication-overuse headache exists in CH and whether the existing criteria for medication-overuse headache are a suitable diagnostic tool in CH. We aimed to examine the prevalence of medication-overuse and
Nunu Lund, Marie-Louise Kulas Søborg, Louise Ninett Carlsen, Rigmor Højland Jensen, Anja Sofie Petersen   +4 more
openaire   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Understanding Women's Career‐Related Behaviors in the Context of Endometriosis: A Psychological Contract Breach Approach

Gender, Work &Organization, EarlyView.
ABSTRACT The stigma and taboo surrounding menstruation and reproductive health perpetuate a culture of silence and shame, limiting open discussions about endometriosis. Although existing research has examined its general impact on work, little attention has been paid to its influence on career‐related behaviors.
Achmet Véronique
wiley   +1 more source

Study protocol: Brief intervention for medication overuse headache - A double-blinded cluster randomised parallel controlled trial in primary care

BMC Neurology, 2012
Background Chronic headache (headache ≥ 15 days/month for at least 3 months) affects 2–5% of the general population. Medication overuse contributes to the problem.
Kristoffersen Espen, Straand Jørund, Benth Jūratė, Russell Michael, Lundqvist Christofer   +4 more
doaj   +1 more source

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja   +5 more
wiley   +1 more source

Nasal decongestant and chronic headache: a case of naphazoline overuse headache? [v1; ref status: indexed, http://f1000r.es/1t2]

F1000Research, 2013
Background: Chronic headache is an incapacitating condition afflicting patients at least for 15 days per month. In the most cases it is developed as a consequence of an excessive use of symptomatic drugs.
Cherubino Di Lorenzo, Gianluca Coppola, Valeria La Salvia, Francesco Pierelli   +3 more
doaj   +1 more source

Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine–Diary (AIM‐D) individual and activity limitation items, and complete improvement in AIM‐D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 ...
Richard B. Lipton, Pranav Gandhi, Andreas R. Gantenbein, Brett Dabruzzo, Karen Carr, Jonathan Stokes, Molly Duan, Rashmi B. Halker Singh, Hsiangkuo Yuan, Dawn C. Buse   +9 more
wiley   +1 more source

In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?

Arquivos de Neuro-Psiquiatria
Medication-overuse headache (MOH) was first described in 1951 with ergotamine overuse. Since then, much has been studied about its risk factors, pathophysiology, prevention, and treatment. Despite this, many people still suffer from this condition.
Renata Gomes Londero
doaj   +1 more source

Integrative East–West Medicine Intervention for Chronic Daily Headache: A Case Report and Care Perspective

Global Advances in Health and Medicine, 2020
Chronic daily headache is a group of headache syndromes including most commonly chronic migraine and chronic tension-type headache, which often overlap, are complicated by medication overuse and are disabling, costly, and variable responsive to western ...
Justin G Laube MD, Thais Salles Araujo MD, Lawrence B Taw MD, FACP   +2 more
doaj   +1 more source

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno, Tyla I. Alexander, William K. Karlsson, Haidar M. Al‐Khazali, Michael L. Garelja, Rune H. Christensen, Messoud Ashina, Debbie L. Hay, Håkan Ashina   +8 more
wiley   +1 more source